MANNKIND CORPORATION

Analyst Reco. MannKind Corporation

Equities

MNKD

US56400P7069

Market Closed - Nasdaq Other stock markets 04:00:01 2024-05-01 pm EDT			5-day change	1st Jan Change
4.325 ^USD	+5.23%		+3.22%	+18.82%

Apr. 30	MannKind Corporation to Proceed with Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases	CI
Apr. 29	MannKind Gets FDA Approval to Begin Phase 3 Trial of Lung Disease Treatment	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Adjusts MannKind Price Target to $5.50 From $6.50, Maintains Outperform Rating	Nov. 14	MT
Wedbush Initiates MannKind at Outperform With $10 PT; Says Orphan Lung Pipeline Presents Potential for Real Future Value-Creation, Optionality	23-10-10	MT
HC Wainwright Adjusts Price Target on MannKind to $7.50 From $7, Keeps Buy Rating	23-08-14	MT
HC Wainwright Adjusts Price Target on MannKind to $7 From $6, Keeps Buy Rating	23-02-27	MT
SVB Securities Adjusts Price Target on MannKind to $6 From $5, Maintains Outperform Rating	22-11-09	MT
HC Wainwright Trims MannKind's Price Target to $6 From $6.50, Maintains Buy Rating	22-02-28	MT
MANNKIND : Initiated at Sector Perform by RBC, Price Target Set at $5/Share	21-05-14	MT
MANNKIND : SVB Leerink Adjusts Price Target on MannKind to $5 From $3, Maintains Outperform Rating	21-03-05	MT
MANNKIND : BTIG Research Adjusts MannKind PT to $8 From $4, Maintains Buy Rating	21-02-24	MT
MANNKIND : Oppenheimer Adjusts MannKind PT to $7 From $3, Maintains Outperform Rating	21-02-17	MT
MANNKIND : Oppenheimer Adjusts MannKind PT to $3 From $2.50, Maintains Outperform Rating	20-11-05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Like the pros, access all the transcripts and spot the best opportunities before anyone else.

Unlock them now!

fermer